Clinical trials: Cervical Intraepithelial Neoplasia Grade 3
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2
Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia
Phase I trial to study the effectiveness of photodynamic therapy with lutetium texaphyrin in treating patients who have cervical intraepithelial neoplasia.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
- Trial name
- NCT00005808
- Testing
- motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Precancerous Condition
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Precancerous lesions of the cervix occur frequently and are treatable. This justifies a population-based screening program. Following an abnormal Pap smear, patients are referred for a colposcopic exam to confirm the…
- Trial name
- MDC_Algo (NCT01094132)
- Testing
- Multispectral Digital Colposcope (MDC)
- Where
- 3 sites in United States, Canada
- Volunteers
- 551 people
- Sponsor
- British Columbia Cancer Agency
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
This phase I research protocol is designed to assess immunogenicity and clinical endpoints in patients with human papillomavirus (HPV) 16 cervical intraepithelial neoplasia (CIN)2/3.
- Trial name
- NCT02354534
- Testing
- Artesunate Suppositories
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
This is a randomized Phase II, three arm control trial in patients with Cervical Intraepithelial Neoplasia (CIN) 2/3 high grade cervical dysplasia.
- Trial name
- NCT02864147
- Testing
- 9-valent HPV vaccine, Imiquimod
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Yale University
Atypical Squamous Cell of Undetermined Significance, ASC-US
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population
- Conditions
- Atypical Squamous Cell of Undetermined Significance, ASC-US, Atypical Glandular Cells of Uncertain Significance, AGUS
- Trial name
- NCT07211204
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Cervical Intraepithelial Neoplasia
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
- Trial name
- NCT02139267
- Testing
- GX-188E
- Where
- 4 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Genexine, Inc.
Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer…
- Conditions
- Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I, Cervix; Intraepithelial Neoplasia, Grade II
- Trial name
- NCT06263582
- Testing
- Artesunate pessary, blood draws for pharmacokinetics of the study drug
- Where
- Kenya
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Intraepithelial Neoplasia
ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial
The present primary therapy of cervical intraepithelial neoplasia (CIN) grade 3 and persistent CIN 2 represents conisation. Surgical treatment can cause perioperative (infection, bleeding in in 5-10%) and postoperative (increased…
- Trial name
- ITIC (NCT00941252)
- Testing
- Topical imiquimod therapy
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Cervical Intraepithelial Neoplasia Grade 2/3, Adenocarcinoma in Situ
Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
To identify: 1) Whether being informed infrequently results about screening is at least as a) safe and b) accurate as frequently obtaining all information from (the present combination of opportunistic/organized) cervical…
- Trial name
- HPV400 (NCT04755517)
- Testing
- Frequent information of cytological/ HPV DNA screening results
- Where
- 18 sites in Finland
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
- Trial name
- NCT00054041
- Testing
- HspE7, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.
- Trial name
- NCT03206138
- Testing
- GX-188E, GX-I7, GX-188E, Imiquimod
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital
Urothelial Carcinoma, Melanoma
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR.
- Conditions
- Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
- Trial name
- NCT02986867
- Testing
- SAbR Treatment of Lesions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
CIN 2/3
Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral…
- Trial name
- NeoART-CIN (NCT07095478)
- Testing
- Artesunate
- Where
- 5 sites in Malaysia
- Volunteers
- 28 people
- Sponsor
- Metanoic Health Ltd.
Human Papilloma Virus Infection, Carcinoma in Situ of Uterine Cervix
Community-Driven Cervical Cancer Prevention in Western Kenya
There are many challenges to implementation of cervical cancer prevention in resource-limited countries, despite evidence based screening and treatment strategies.
- Trial name
- NCT02124252
- Testing
- Community-based testing with standard linkage to care, Community-based HPV testing with enhanced linkage to care
- Where
- Kenya
- Volunteers
- 7,200 people, healthy volunteers welcome
- Sponsor
- Duke University
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Precancerous Condition
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- SAGE (NCT00629577)
- Testing
- microarray analysis, flow cytometry, biopsy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Cervical Intraepithelial Neoplasia Grade 2/3
Effectiveness of Cervical Screening in HPV Vaccinated Women
The main objective of the study is to identify whether or not being informed infrequently results about screening is: 1) At least as safe and accurate as frequently obtaining all information from the present combination of…
- Trial name
- HPV-004 (NCT02149030)
- Testing
- Cytological screening in A1 and A3
- Where
- 31 sites in Finland
- Volunteers
- 6,958 people, healthy volunteers welcome
- Sponsor
- Tampere University